Autolus Therapeutics plc
AUTL
$2.13
-$0.10-4.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 927.90% | 644.94% | 406.67% | 185.17% | -14.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 927.90% | 644.94% | 406.67% | 185.17% | -14.16% |
| Cost of Revenue | 52.82% | 72.09% | -15.19% | -4.10% | -34.63% |
| Gross Profit | 18.57% | -11.28% | 38.94% | 18.29% | 35.88% |
| SG&A Expenses | 22.35% | 25.51% | 52.00% | 74.07% | 90.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.15% | 37.61% | 42.49% | 47.44% | 45.99% |
| Operating Income | 1.13% | -12.11% | -25.65% | -39.95% | -49.52% |
| Income Before Tax | -23.03% | -30.31% | 18.51% | 4.41% | -5.92% |
| Income Tax Expenses | -83.80% | 29.08% | 11,158.54% | 205,400.00% | 29,023.08% |
| Earnings from Continuing Operations | -21.35% | -30.30% | 16.81% | 2.65% | -7.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.35% | -30.30% | 16.81% | 2.65% | -7.62% |
| EBIT | 1.13% | -12.11% | -25.65% | -39.95% | -49.52% |
| EBITDA | 1.96% | -11.61% | -25.68% | -40.45% | -50.38% |
| EPS Basic | -21.33% | -24.40% | 30.08% | 26.41% | 25.80% |
| Normalized Basic EPS | -23.08% | -24.43% | 31.31% | 27.49% | 26.95% |
| EPS Diluted | -21.33% | -24.40% | 30.08% | 26.41% | 25.80% |
| Normalized Diluted EPS | -23.08% | -24.43% | 31.31% | 27.49% | 26.95% |
| Average Basic Shares Outstanding | 0.01% | 4.32% | 14.67% | 27.30% | 43.05% |
| Average Diluted Shares Outstanding | 0.01% | 4.32% | 14.67% | 27.30% | 43.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |